Short answer · Medically reviewed summary · Last updated: 2026-05-08
Carcinoid Syndrome is a clinical condition resulting from the systemic release of vasoactive substances, such as serotonin, by neuroendocrine tumors (NETs). It is also commonly referred to as serotonin syndrome (though this term is more frequently used for drug-induced reactions) or malignant carcinoid syndrome when metastatic disease is present. Why does Carcinoid Syndrome have multiple names? The nomenclature for Carcinoid Syndrome has evolved as our understanding of tumor biology has progressed.
Carcinoid Syndrome synonyms
Other names for Carcinoid Syndrome: synonyms, acronyms and related terms used by doctors and patients.
Carcinoid Syndrome is a clinical condition resulting from the systemic release of vasoactive substances, such as serotonin, by neuroendocrine tumors (NETs). It is also commonly referred to as serotonin syndrome (though this term is more frequently used for drug-induced reactions) or malignant carcinoid syndrome when metastatic disease is present.
Why does Carcinoid Syndrome have multiple names?
The nomenclature for Carcinoid Syndrome has evolved as our understanding of tumor biology has progressed. Historically, these tumors were called "carcinoids" because they were thought to be "carcinoma-like" but less aggressive. As medical science identified that these tumors originate from the diffuse neuroendocrine system, the term Neuroendocrine Tumor (NET) syndrome has become more clinically accurate. You may see older medical records or literature refer to the condition as argentaffinoma syndrome, reflecting the staining properties of the tumor cells under a microscope.
What are the official medical classifications for this condition?
In formal medical coding and clinical literature, Carcinoid Syndrome is classified using specific international standards to ensure consistency for patients and providers:
- ICD-10: Classified under E34.0 (Carcinoid syndrome).
- Orphanet: Recognized as ORPHA:135 (Carcinoid syndrome).
- OMIM: Often discussed within the context of genetic predisposition to neuroendocrine tumors, such as Multiple Endocrine Neoplasia type 1 (MEN1).
Which terminology is currently preferred by specialists?
While Carcinoid Syndrome remains the most widely recognized term in patient communities—including the 49 members currently sharing experiences on DiseaseMaps.org—modern oncology prefers the term Neuroendocrine Tumor-associated syndrome. This shift helps distinguish the systemic hormonal symptoms from the underlying tumor biology. Using these specific terms when searching medical databases will yield the most current research on treatment protocols and clinical trials.
Next steps
- Consult an endocrinologist or an oncologist specializing in neuroendocrine tumors to clarify your specific diagnosis.
- Use the term "Carcinoid Syndrome" alongside "Neuroendocrine Tumor" when searching clinical trial databases like ClinicalTrials.gov.
- Connect with the 49 members in the DiseaseMaps community to share experiences and coping strategies.
- Request a copy of your pathology report to confirm the exact classification of your tumor.
Medical Disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
References
- Orphanet: Rare Disease Database (ORPHA:135)
- NIH Genetic and Rare Diseases Information Center (GARD)
- World Health Organization (WHO) Classification of Tumours
- ENETS (European Neuroendocrine Tumor Society) Guidelines
